• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.

    1/22/26 6:55:10 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    Surrozen, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    86889P208

    (CUSIP Number)


    James Evangelista, CFO
    The Column Group III, LP, 1 Letterman Drive, Building D, Suite M-9
    San Francisco, CA, 94129
    (415) 865-2050

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    01/20/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group III GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,962,544.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,962,544.00
    11Aggregate amount beneficially owned by each reporting person

    2,962,544.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    28.6 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 900,292 shares of Common Stock held of record by TCG III LP (as defined in Item 2(a) below), (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in its Current Report on Form 8-K filed with the Commission on March 28, 2025 (the Form 8-K), (iii) warrants to purchase 5,218 shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, (iv) 1,016,658 shares of Common Stock held of record by TCG III-A LP (as defined in Item 2(a) below), (v) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K and (vi) warrants to purchase 5,893 shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement. TCG III GP LP is the general partner of each of TCG III LP and TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes (a) warrants to purchase 594,625 shares of Common Stock held by TCG III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations and (b) warrants to purchase 671,518 shares of Common Stock held by TCG III-A LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 10,368,376 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement, plus (iii) 5,218 shares underlying warrants to purchase shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, plus (iv) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement, plus (v) 5,893 shares underlying warrants to purchase shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group III, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,391,340.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,391,340.00
    11Aggregate amount beneficially owned by each reporting person

    1,391,340.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 900,292 shares of Common Stock held of record by TCG III LP, (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K and (iii) warrants to purchase 5,218 shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement. TCG III GP LP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes warrants to purchase 594,625 shares of Common Stock held by TCG III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 9,813,830 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement,plus (iii) 5,218 shares underlying warrants to purchase shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group III-A, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,571,204.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,571,204.00
    11Aggregate amount beneficially owned by each reporting person

    1,571,204.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    15.9 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 1,016,658 shares of Common Stock held of record by TCG III-A LP, (ii) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K and (iii) warrants to purchase 5,893 shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement. TCG III GP LP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes warrants to purchase 671,518 shares of Common Stock held by TCG III-A LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 9,877,328 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement, plus (iiI) 5,893 shares underlying warrants to purchase shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group Opportunity III, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    862,068.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    862,068.00
    11Aggregate amount beneficially owned by each reporting person

    862,068.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.8 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 344,827 shares of Common Stock held of record by TCG Opportunity III LP (as defined in Item 2(a)) and (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K. TCG Opportunity III GP LP (as defined in Item 2(a)) is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC (as defined in Item 2(a)) is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes warrants to purchase 431,034 shares of Common Stock held by TCG Opportunity III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 9,840,023 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group Opportunity III GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    862,068.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    862,068.00
    11Aggregate amount beneficially owned by each reporting person

    862,068.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.8 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 344,827 shares of Common Stock held of record by TCG Opportunity III LP and (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes warrants to purchase 431,034 shares of Common Stock held by TCG Opportunity III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 9,840,023 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    TCG Opportunity III GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    862,068.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    862,068.00
    11Aggregate amount beneficially owned by each reporting person

    862,068.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.8 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Consists of (i) 344,827 shares of Common Stock held of record by TCG Opportunity III LP and (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes warrants to purchase 431,034 shares of Common Stock held by TCG Opportunity III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 9,840,023 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    Tim Kutzkey
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,824,612.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,824,612.00
    11Aggregate amount beneficially owned by each reporting person

    3,824,612.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    35.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 900,292 shares of Common Stock held of record by TCG III LP, (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K, (iii) warrants to purchase 5,218 shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, (iv) 1,016,658 shares of Common Stock held of record by TCG III-A LP, (v) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K, (vi) warrants to purchase 5,893 shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement, (vii) 344,827 shares of Common Stock held of record by TCG Opportunity III LP and (viii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K. TCG III GP LP is the general partner of each of TCG III LP and TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to the securities held by TCG Opportunity III LP. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to the securities held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing partners of TCG III GP LP and the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes (a) warrants to purchase 594,625 shares of Common Stock held by TCG III, LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations, (b) warrants to purchase 671,518 shares of Common Stock held by TCG III-A LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations and (c) 431,034 shares of Common Stock held by TCG Opportunity III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 10,885,617 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement, plus (iii) 5,218 shares underlying warrants to purchase shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, plus (iv) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement, plus (v) 5,893 shares underlying warrants to purchase shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement, plus (vi) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    Peter Svennilson
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    SWEDEN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,824,612.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,824,612.00
    11Aggregate amount beneficially owned by each reporting person

    3,824,612.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    35.1 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 900,292 shares of Common Stock held of record by TCG III LP, (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K, (iii) warrants to purchase 5,218 shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, (iv) 1,016,658 shares of Common Stock held of record by TCG III-A LP, (v) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K, (vi) warrants to purchase 5,893 shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement, (vii) 344,827 shares of Common Stock held of record by TCG Opportunity III LP and (viii) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement in the second tranche of the Issuer's private placement transaction as disclosed by the Issuer in the Form 8-K. TCG III GP LP is the general partner of each of TCG III LP and TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to the securities held by TCG Opportunity III LP. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to the securities held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors, are the managing partners of TCG III GP LP and the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. Excludes (a) warrants to purchase 594,625 shares of Common Stock held by TCG III, LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations, (b) warrants to purchase 671,518 shares of Common Stock held by TCG III-A LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations and (c) 431,034 shares of Common Stock held by TCG Opportunity III LP which are not exercisable within 60 days of this Statement due to beneficial ownership limitations. Based on 10,885,617 shares outstanding, comprised of (i) 9,322,782 shares of Common Stock outstanding as of November 17, 2025, as provided by the Issuer to the Reporting Persons, plus (ii) 485,830 shares of Common Stock which TCG III LP has the right to acquire within 60 days of this Statement, plus (iii) 5,218 shares underlying warrants to purchase shares of Common Stock held by TCG III LP which are exercisable within 60 days of this Statement, plus (iv) 548,653 shares of Common Stock which TCG III-A LP has the right to acquire within 60 days of this Statement, plus (v) 5,893 shares underlying warrants to purchase shares of Common Stock held by TCG III-A LP which are exercisable within 60 days of this Statement, plus (vi) 517,241 shares of Common Stock which TCG Opportunity III LP has the right to acquire within 60 days of this Statement.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    Surrozen, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    171 Oyster Point Blvd., Suite 400, South San Francisco, CALIFORNIA , 94080.
    Item 1 Comment:
    Explanatory Note: This Amendment No. 5 (this Amendment No. 5) supplements and amends the Schedule 13D relating to the Common Stock of the Issuer that was filed with the Commission on August 23, 2021, as amended by Amendment No. 1 that was filed with the Commission on February 13, 2023, by Amendment No. 2 that was filed with the Commission on April 8, 2024, by Amendment No. 3 that was filed with the Commission on April 17, 2024 and Amendment No. 4 that was filed with the Commision on March 28, 2025 (collectively, the Original Schedule 13D). This Amendment No. 5 is being filed to report the purchases by the Reporting Persons of certain securities of the Issuer as set forth in Item 3 of this Statement. Only those items that are reported are hereby amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.
    Item 2.Identity and Background
    (a)
    This Statement is being filed by The Column Group III, LP (TCG III LP), The Column Group III-A, LP (TCG III-A LP), The Column Group III GP, LP (TCG III GP LP), The Column Group Opportunity III, LP (TCG Opportunity III LP), The Column Group Opportunity III GP, LP (TCG Opportunity III GP LP), TCG Opportunity III GP, LLC (TCG Opportunity III GP LLC, together with TCG III LP, TCG III-A LP, TCG III GP LP, TCG Opportunity III LP, and TCG Opportunity III GP LP, the Reporting Entities), Tim Kutzkey, a member of the Issuer's board of directors and Peter Svennilson. The Reporting Entities, Mr. Svennilson and Dr. Kutzkey are collectively referred to as the Reporting Persons. Peter Svennilson has been added to this Statement as a Reporting Person as a result of the retirement of a managing partner of TCG III GP LP and a managing member of TCG Opportunity III GP LLC. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached hereto as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.
    (b)
    The address of the principal offices of each Reporting Entity 1 Letterman Drive, Building D, Suite M-900, San Francisco, CA 94129.
    (c)
    Each of TCG III LP, TCG III-A LP and TCG Opportunity III LP is a venture capital investment entity. TCG III GP LP is the general partner of each of TCG III LP and TCG III-A LP. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Dr. Kutzkey and Peter Svennilson are the managing partners of TCG III GP LP and the managing members of TCG Opportunity III GP LLC, and are each engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes.
    (d)
    During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Each of TCG III GP LP, TCG III LP, TCG III-A LP, TCG Opportunity III LP and TCG Opportunity III GP LP is a limited partnership organized under the laws of the State of Delaware. TCG Opportunity III GP LLC is a limited company organized under the laws of the State of Delaware. Dr. Kutzkey is a citizen of the United States of America. Mr. Svennilson is a citizen of Sweden.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Original Schedule 13D is hereby amended by adding the following as the last paragraphs thereof: On November 13, 2025, TCG III LP purchased 148,150 shares of Common Stock for a purchase price of $12.65 per share or $1,874,097.50 in the aggregate. On November 13, 2025, TCG III-A LP purchased 167,307 shares of Common Stock for a purchase price of $12.65 per share or $2,116,433.55 in the aggregate. On December 4, 2025, TCG III LP purchased 2,475 shares of Common Stock for a purchase price of $17.347 per share or $42,933.83 in the aggregate. On December 4, 2025, TCG III-A LP purchased 2,791 shares of Common Stock for a purchase price of $17.347 per share or $48,415.48 in the aggregate. On December 5, 2025, TCG III LP purchased 14,503 shares of Common Stock for a purchase price of $19.5409 per share or $283,401.67 in the aggregate. On December 5, 2025, TCG III-A LP purchased 16,381 shares of Common Stock for a purchase price of $19.5409 per share or $320,099.48 in the aggregate. On January 6, 2026, TCG III LP purchased 7,097 shares of Common Stock for a purchase price of $19.8872 per share or $141,139.46 in the aggregate. On January 6, 2026, TCG III-A LP purchased 8,003 shares of Common Stock for a purchase price of $19.8872 per share or $159,157.26 in the aggregate. On January 13, 2026, TCG III LP purchased 5,861 shares of Common Stock for a purchase price of $19.8041 per share or $116,071.83 in the aggregate. On January 13, 2026, TCG III-A LP purchased 6,609 shares of Common Stock for a purchase price of $19.8041 per share or $130,885.30 in the aggregate. On January 14, 2026, TCG III LP purchased 2,596 shares of Common Stock for a purchase price of $19.9883 per share or $51,889.63 in the aggregate. On January 14, 2026, TCG III-A LP purchased 2,927 shares of Common Stock for a purchase price of $19.9883 per share or $58,505.75 in the aggregate. On January 15, 2026, TCG III LP purchased 5,590 shares of Common Stock for a purchase price of $19.889 per share or $111,179.51 in the aggregate. On January 15, 2026, TCG III-A LP purchased 6,303 shares of Common Stock for a purchase price of $19.889 per share or $125,360.37 in the aggregate. On January 16, 2026, TCG III LP purchased 1,204 shares of Common Stock for a purchase price of $20.00 per share or $24,080.00 in the aggregate. On January 16, 2026, TCG III-A LP purchased 1,358 shares of Common Stock for a purchase price of $20.00 per share or $27,160.00 in the aggregate. On January 20, 2026, TCG III LP purchased 8,484 shares of Common Stock for a purchase price of $19.5999 per share or $166,285.55 in the aggregate. On January 20, 2026, TCG III-A LP purchased 9,568 shares of Common Stock for a purchase price of $19.5999 per share or $187,531.84 in the aggregate.
    Item 4.Purpose of Transaction
     
    The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Items 7-11 of the cover pages of this Amendment No. 5.
    (b)
    See Items 7-11 of the cover pages of this Amendment No. 5.
    (c)
    Except as reported in this Statement, none of the Reporting Persons has affected any transactions in the Issuer's securities within the past 60 days.
    (d)
    Under certain circumstances set forth in the limited partnership agreements of TCG III LP, TCG III-A LP and TCG Opportunity III LP, the general partner and limited partners of each of TCG III LP, TCG III-A LP and TCG Opportunity III LP may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1: Joint Filing Agreement, dated January 22, 2026, by and among the Reporting Persons (filed herewith).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Column Group III GP, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    The Column Group III, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    The Column Group III-A, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    The Column Group Opportunity III, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    The Column Group Opportunity III GP, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    TCG Opportunity III GP, LLC
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    Tim Kutzkey
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
     
    Peter Svennilson
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:01/22/2026
    Get the next $SRZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:35:33 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kutzkey Tim bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:31:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr

    2/5/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen to Present at Upcoming Healthcare Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern Time 8th Annual Evercore Healthcare Conference on December 3, 2025Surrozen Fireside Chat at 12:25 PM Pacific Time/3:25 PM Eastern Time Interested parties may access the audio webcast for the confer

    11/25/25 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of employment with Surrozen. The awards were granted under Surrozen's 2025 Equity Inducement Plan and provides for the granting of equity awards to new employees of Surrozen in

    11/12/25 5:01:40 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

    SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    2/5/26 4:28:31 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Inc. filed SEC Form 8-K: Leadership Update

    8-K - Surrozen, Inc./DE (0001824893) (Filer)

    1/30/26 4:08:58 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.

    SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)

    1/22/26 6:55:10 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Surrozen with a new price target

    H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

    1/30/25 7:17:42 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen upgraded by Guggenheim with a new price target

    Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

    1/3/25 7:50:23 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B of A Securities initiated coverage on Surrozen with a new price target

    B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

    10/11/21 7:02:26 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Tcg Crossover Gp Ii, Llc claimed ownership of 1,274,010 shares (SEC Form 3)

    3 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/28/26 5:51:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Williams Charles O

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/26/26 4:39:41 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    View All

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

    SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

    4/5/23 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

    9/23/21 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Financials

    Live finance-specific insights

    View All

    Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

    Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

    3/22/23 4:01:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

    SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

    3/20/23 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/14/24 4:34:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/13/24 5:42:02 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/8/24 11:26:54 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care